Watch Other Hep C Drug Makers on Pharmasset (VRUS) QUANTUM News: INHX IDIX ACHN
Tweet
Share
E-mailGet Alerts VRUS Hot Sheet
Join SI Premium – FREE
While shares of Pharmasset (Nasdaq: VRUS) are down only very modestly following news it has amended its QUANTUM trial, traders should be watching the makers of other Hepatitis C drugs: shares of Inhibitex (Nasdaq: INHX) are down 42 percent, shares of Idenix (Nasdaq: IDIX) are down 13 percent and shares of Achillion (Nasdaq: ACHN) down almost 8 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Startup Micro1 offering $12.5M for Spirit Airlines data - Business Insider
- Nvidia plans China chip shipments with export-compliant AI processor - The Information
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
